# Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call
Canonical URL: https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-schedules-first-q4-and-fy-2023-earnings-call
Ticker: PTIX
Company: Protagenic Therapeutics
Source: Protagenic Therapeutics
Published: 2024-03-25 17:00 EST
Original Source URL: https://www.pressviewer.com
## Summary

<div class="b2iNewsItemBodyDiv"><p><i><strong>Call Scheduled for Monday, April 1<sup>st</sup>, 2024, at 4:30 pm ET</strong></i></p><p><strong>NEW YORK, NY / ACCESSWIRE / March 25, 2024 /</strong> Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced that the Company plans to hold its fir

## Article Body
Call Scheduled for Monday, April 1st, 2024, at 4:30 pm ET

NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced that the Company plans to hold its first investor earnings call to discuss the results contained in its FY 2023 Form 10K, which it plans to file that day, and its outlook for FY 2024.

The Company plans to hold...
## Recent Company News
- 2026-05-19 08:15 EST — [Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-engages-floyd-regulatory-strategic-consulting-as-regulatory-affairs-advisor-and-danforth-health-as-strategic-operations-partner) — Source: Protagenic Therapeutics
- 2026-04-23 08:15 EST — [Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-appoints-industry-veteran-bill-nichols-jr-as-president-to-accelerate-advancement-of-first-in-class-tcap-pathway-therapy-pt00114) — Source: Protagenic Therapeutics
- 2026-03-17 08:00 EST — [Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-completes-phytanix-separation-strengthens-balance-sheet-and-repositions-the-company-around-pt00114) — Source: Protagenic Therapeutics
- 2026-03-10 08:00 EST — [Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-upgrades-from-otc-pink-to-otcqb-venture-market) — Source: Protagenic Therapeutics
- 2025-12-09 08:46 EST — [Results from Phase 1 Multiple-Dose Study of PT00114](https://biopharmsignal.com/news/PTIX/results-from-phase-1-multiple-dose-study-of-pt00114) — Source: Protagenic Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)